Holocene Advisors’s Vaxcyte PCVX Stock Holding History

Holocene Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,613	Closed	-$701K	–	843
2022 Q4	$701K	Buy	+14,613	New	+$573K	﹤0.01%	592

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Holocene Advisors's PCVX Position: Q1 2023 in Review

Holocene Advisors sold out of Vaxcyte (PCVX) in Q1 2023, closing a stake of 14,613 shares — an estimated $701K sold.

Holocene Advisors first reported a position in PCVX in Q4 2022 and held it in 1 quarter. The position peaked at $701K in Q4 2022. 187 funds tracked by Wall St. Rank hold PCVX as of Q1 2023.

Holocene Advisors reported no remaining Vaxcyte position as of Q1 2023 after selling out during the quarter.
Holocene Advisors sold 14,613 Vaxcyte shares in Q1 2023, an estimated $701K.
Holocene Advisors first reported a position in Vaxcyte in Q4 2022 and held it in 1 quarter.
Holocene Advisors's Vaxcyte position peaked at $701K in Q4 2022.
187 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2023.

Based on Holocene Advisors's 13F filing for Q1 2023, filed 15 May 2023.